Test drug KC1036 in people with advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor cancer that has come back or spread.
- You’ve tried standard treatments (like chemo or immunotherapy) and your cancer grew, didn’t respond, or you couldn’t tolerate them.
- You have at least one measurable spot the doctors can track on scans.
- Your overall strength is good (ECOG performance status 0 or 1).
- You’re expected to live more than 12 weeks and you can sign consent.
- Brain metastases are not allowed unless any symptoms can be controlled within 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.